Clinical Trial Detail

NCT ID NCT01883362
Title Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

acute myeloid leukemia

Therapies

Midostaurin

Age Groups: adult

Additional content available in CKB BOOST